GleamWall
中文EN

CVKD Cadrenal Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1937993 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.8%
TTM EPS YoY57.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-358.3%
ROA-267.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets16.0%
Debt / equity0.00x
Current ratio6.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$4.10M$4.21M
SG&A expense$9.35M$6.75M
Operating income-$13.46M-$10.96M
Pretax income-$13.24M-$10.65M
Net income-$13.24M-$10.65M
EBITDA-$13.45M-$10.96M
EPS (basic)-6.64-8.73
EPS (diluted)-6.64-8.73
Dividends declared per share16.5016.50
Weighted avg. shares (diluted)1.99M1.22M
Balance sheet
Cash & equivalents$4.01M$10.02M
Current assets$4.32M$10.11M
PP&E, net$5,174$6,944
Total assets$4.33M$10.12M
Current liabilities$1.59M$2.68M
Total liabilities$1.59M$2.68M
Shareholders' equity$2.74M$7.44M
Shares outstanding2.34M1.78M
Cash flow statement
Operating cash flow-$12.60M-$7.36M
Capital expenditure$5,104$6,537
Free cash flow-$12.61M-$7.36M
Investing cash flow-$5,104-$6,537
Financing cash flow$6.60M$8.98M
Depreciation & amortization$6,874$1,880
Stock-based compensation$1.94M$1.42M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.